[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649613":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":47,"responsibleParty":69,"collaborators":26,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":74,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":26,"studyType":86,"phases":87,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":100,"whyStopped":26,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Benha University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Drospirenone","EXPERIMENTAL","50 cases will receive drospirenone in the form of 1 tablet \u002F d when the leading follicle reaches 14 mm till hCG trigger day",[13],"Drug: Drospirenone drug",{"label":15,"type":16,"description":17,"interventionNames":18},"cetrorelix","ACTIVE_COMPARATOR","50 cases will receive cetrorelix when the leading follicle reaches 14 mm till hCG trigger day",[19],"Drug: Cetrorelix 0.25 mg",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Drospirenone drug","A drug drospirenone in the form of 1 tablet \u002F d from 14 mm follicle till hCG trigger day",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Cetrorelix 0.25 mg","Cetrorelix a drug injection daily sc. from 14 mm follicle till hCG trigger day",[15],[32],{"name":33,"affiliation":34,"role":35},"Ahmed s Saad, phD","Professor of OB & GYN","STUDY_DIRECTOR",[37,43],{"name":38,"role":39,"phone":40,"phoneExt":41,"email":42},"Ahmed S Saad, phD","CONTACT","+201221709989","020","drahmedsaad@live.com",{"name":44,"role":39,"phone":45,"phoneExt":41,"email":46},"Walid A Abdel Halim, phD","0201228343376","waleedabdellateef@gmail.com",[48],{"facility":49,"status":26,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Hawaa Fertility Center","Banhā","Qalyubia Governorate","13512","Egypt","EG",{"type":56,"coordinates":57},"Point",[58,59],31.1842,30.45977,{"lat":59,"lon":58},[62,65],{"name":63,"role":39,"phone":64,"phoneExt":41,"email":42},"Ahmed s saad, phD","01221709989",{"name":66,"role":39,"phone":67,"phoneExt":41,"email":68},"walid a abdelateef, phD","0201100434632","waleedabdelateef@gmail.com",{"type":70,"investigatorFullName":71,"investigatorTitle":34,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"SPONSOR_INVESTIGATOR","Ahmed Saad","100649613","phase-1-drospirenone-primed-ovarian-stimulation-versus-gnrh-antagonist-protocol-in-poor-ovarian-responders-undergoing-freeze-all-ivficsi-100649613",false,"NCT07736261","Drospirenone-Primed Ovarian Stimulation Versus GnRH Antagonist Protocol in Poor Ovarian Responders Undergoing Freeze-All IVF\u002FICSI","Drospirenone-Primed Ovarian Stimulation (PPOS) Versus Flexible GnRH Antagonist Protocol in Poor Ovarian Responders Undergoing a Freeze-All Strategy: A Pilot Randomized Controlled Trial","PPOS","Inclusion Criteria:\n\n* Spontaneous menstrual cycles (21-35 days)\n* Poor ovarian response per Bologna criteria (≥2 of 3): advanced age ≥40 or risk factor for POR; previous poor response (≤3 oocytes with conventional stimulation); abnormal ovarian reserve (AFC \\\u003C7 or AMH \\\u003C1.1 ng\u002FmL)\n* POSEIDON group recorded at enrollment (1-4) for stratified randomization and pre-specified subgroup description - corrects a known limitation of Bologna-only classification, which pools biologically distinct POR phenotypes\n* Indication for IVF\u002FICSI\n* Willing and able to undergo mandatory freeze-all\u002FFET protocol\n* Signed informed consent, including explicit acknowledgment that fresh transfer is not offered in either study arm\n\nExclusion Criteria:\n\n* Contraindication to ovarian stimulation\n* Known müllerian anomaly\n* Uncontrolled systemic disease\n* 5 prior failed IVF attempts\n* Known contraindication to drospirenone (per product labeling, e.g., renal impairment, adrenal insufficiency, conditions predisposing to hyperkalemia)","FEMALE","20 Years","42 Years",{"count":84,"type":85},100,"ESTIMATED","INTERVENTIONAL",[88,89],"PHASE1","PHASE2","Participants will:\n\n* Take either drospirenone (a daily pill) or the standard daily injection during their ovarian stimulation cycle, alongside their regular fertility hormone injections\n* Undergo egg retrieval, with all resulting embryos frozen (no fresh embryo transfer in this study)\n* Have a frozen embryo transferred in a later cycle\n* Complete two short questionnaires about their treatment experience - once before starting the injections\u002Fpills, and once after the stimulation phase ends\n* Be followed to determine if the embryo transfer results in a pregnancy",[92,93],"Poor Ovarian Reserve","Infertility (IVF Patients)",[95,96,9,97,98,99],"poor ovarian response","diminished ovarian reserve","progestin primed ovarian stimulation","GnRH antagonist","Freeze all","NOT_YET_RECRUITING","2026-07-29",{"date":103,"type":104},"2026-07-30","ACTUAL",{"date":106,"type":85},"2026-08",{"date":108,"type":85},"2027-11",{"name":71,"class":6},1]